Customise your Experience
Select areas of interest to create an account and personalise your Campus experience
More about Science
Choose a therapeutic area to find related scientific content
Diabetes
Dyslipidaemia
Neurology
.png/jcr:content/MicrosoftTeams-image%20(16).png)
Oncology
Rare Blood Disorders
Rare Diseases
Thrombosis
Explore Content
Explore the most recently added content
Prescribing Information can be found through the links in the Product Cards at the bottom of the page
.png/jcr:content/Monitoring%20thumbnail%20(2).png)
Support for your Patients
Discover the selection of support materials for patients from different therapeutic areas
Nexviadyme ▼ (avalglucosidase alfa) website
Information for patients prescribed Nexviadyme
Multiple Sclerosis
MPS I Physiotherapy Flipbook
Toujeo® Coach | Toujeo® (insulin glargine 300 units/mL)
Our Products
Prescribing Information GB
GB ONLY CONTENT
MAT-GB-2105789 (v6.0)
Date of preparation: February 2023
Prescribing Information GB
Prescribing Information NI
MAT-XU-2200954 (v2.0)
Date of preparation: February 2023
---Copy.png/jcr:content/AUBAGIO_logo_RGB%20(1)%20-%20Copy.png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-XU-2200676 (v3.0)
Date of preparation: August 2022
Prescribing Information GB
Prescribing Information NI
MAT-GB-2105168 (v4.0)
Date of preparation: February 2023
Prescribing Information GB
Prescribing Information NI
MAT-XU-2204064 (v2.0)
Date of preparation: January 2023
Prescribing Information GB
Prescribing Information NI
MAT-XU-2204065 (v2.0)
Date of preparation: January 2023
Clexane
enoxaparin
Prescribing Information UK
MAT-XU-2204397 (v1.0)
Date of preparation: December 2022
Prescribing Information GB
Prescribing Information NI
MAT-GB-2105812 (v3.0)
Date of preparation: February 2023
Prescribing Information GB
Prescribing Information NI
MAT-XU-22014444 (v3.0)
Date of preparation: January 2023
.png/jcr:content/Lemtrada-triangle-logo-product-card%20(1).png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-XU-2200680 (v2.0)
Date of preparation: August 2022
Prescribing Information GB
Prescribing Information NI
MAT-XU-2202651 (v1.0)
Date of preparation: February 2023
.png/jcr:content/Myozyme-logo%20(1).png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-GB-2105179 (v3.0)
Date of preparation: February 2023
NEXVIADYME
avalglucosidase alfa
Prescribing Information GB
GB ONLY CONTENT
MAT-XU-2203480 (v3.0)
Date of preparation: February 2023
PRALUENT
alirocumab
Prescribing Information GB
Prescribing Information NI
MAT-XU-2204604 (v2.0)
Date of preparation: March 2023
MAT-GB-2105435 (v6.0)
Date of preparation: February 2023
Prescribing Information GB
GB ONLY CONTENT
MAT-XU-2205461 (v5.0)
Date of preparation: March 2023
▼ This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.
MAT-XU-2300407 (v1.0)
Date of preparation: February 2023
YOU ARE NOW LEAVING THE SANOFI CAMPUS UK WEBSITE
You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.
Welcome to Sanofi Campus UK
This site is intended for UK healthcare professionals only and contains information on Sanofi UK’s medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales).
MAT-XU-2300297 (v1.0)
Date of Preparation: February 2023